OpenLobby.EU
Explore

Eindhoven University of Technology

TU/e

Eindhoven University of Technology is a young university, founded in 1956 by industry, local government and academia.

Lobbying Activity

Meeting with Christian Ehler (Member of the European Parliament)

16 Sept 2025 · FP10

Meeting with Christian Ehler (Member of the European Parliament)

5 Feb 2025 · European research policy

Meeting with Tom Berendsen (Member of the European Parliament)

7 Nov 2024 · Research, high tech, start-ups

Meeting with Tom Berendsen (Member of the European Parliament)

2 Sept 2024 · Opening of academic year

Meeting with Wopke Hoekstra (Commissioner)

2 Sept 2024 · Opening of the academic year

Meeting with Josianne Cutajar (Member of the European Parliament) and Bureau Européen des Unions de Consommateurs and

4 Apr 2024 · Connecting Europe Days 2024 - Data driven mobility and transport policy and the role of Artificial Intelligence (AI)

Meeting with Diederik Samsom (Cabinet of Executive Vice-President Frans Timmermans)

18 Jan 2022 · CBAM

Meeting with Diederik Samsom (Cabinet of Executive Vice-President Frans Timmermans)

16 Oct 2020 · Online Keynote speech on the European Green Deal

Response to Europe’s Beating Cancer Plan

2 Mar 2020

Eindhoven University of Technology (TU/e) welcomes the roadmap’s overall objectives to improve the prevention, detection, treatment and management of cancer. To achieve these objectives the roadmap rightfully prioritises the use and uptake of digital tools to tackle cancer. By doing so the roadmap underlines the need for investing in innovative tools in all its objectives. The roadmap pays however less attention to the positive impact of medical technologies, which amongst other things contribute to scientific breakthroughs, improve healthcare outcomes and can save costs. The benefits offered by new medical technologies cannot just be expressed in terms of costs and effectiveness alone. TU/e would like to underline therefore that not supporting such innovative medical technologies is not an option. As also stated in the position paper: “Kosten van zorg” (costs of care, see https://www.4tu.nl/nl/publicaties/4tu-position-paper-dt.pdf ) from 4TU (umbrella organisation of four Dutch Universities of Technology), the positive impact of medical technologies on issues such as the satisfaction of patients and healthcare professionals, the workload within healthcare, the labour participation of citizens and patients, the knowledge economy and the (work) attitude of the user / recipient should not be underestimated. As the roadmap rightly mentions cancer can place a burden on our health systems and on society at large with an overall economic impact of cancer in Europe estimated to exceed €100 billion annually. At the same time the roadmap states that analysis of the overall social and economic impact of cancer treatments across the EU is limited. It is therefore important to shift the focus to the total social costs instead of just the health care costs, as technologies might sometimes increase health care costs, they can at the same time reduce social costs, for example by leading to higher participation in labour and productivity, while improving the quality of life. It is clear that a further increase in the costs of care is highly undesirable and that the development of promising cost-effective technologies should be given priority over the development of new cost-increasing technologies. This can only be achieved by estimating the expected impact on costs and health effects at an early stage of technology development by means of Health Technology Assessments (HTA). In addition, cost savings can be achieved by supporting adequate use of new and existing technologies, and by setting strict requirements to broad deployment of new technologies. This requires the involvement of all stakeholders, already at early development stages, but also in further development and application of new iterative assessment methods for medical technologies.
Read full response